**Sunday, March 21**

Arrival and Registration

**Monday, March 22**

Welcome and Keynote Session (Joint)

Helen H. Hobbs, University of Texas Southwestern Medical Center, USA

PNPLA3's Role in NAFLD

Hashem B. El-Serag, Baylor College of Medicine, USA

Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)

Lopa Mishra, George Washington University, USA

TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma

Speaker to be Announced

Short Talks Chosen from Abstracts

Genetics of NAFLD (X5)

Elizabeth K. Speliotes, University of Michigan, USA

Use of GWAS to Identify SNPs Associated with NAFLD

Hannele Yki-Järvinen, University of Helsinki, Finland

Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism

Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA

HSD17B13 and Protection from Liver Disease in Diverse Patient Populations

Short Talks Chosen from Abstracts

The Role of the Microbiome in Hepatobiliary Cancers (X6)

Maria RSCigno, Humanitas University, Italy

The Gut-Liver Axis in Liver Cancer Risk Conditions

Yining Lu, Tsinghua University, China

China’s Innovative Practice on Precision Immunotherapy of Hepatobiliary Carcinoma: From Outcome Prediction to New Therapeutic Approaches

Speaker to be Announced

Short Talks Chosen from Abstracts

Poster Session 1

**Tuesday, March 23**

Role of Lipids in NAFLD (X5)

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA

Circadian Contributions to NAFLD

Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA

Lipid Dysregulation in Inflammation, NASH, and Cancer

Catherine Postic, INSERM, Institut Cochin, France

Altered Insulin Signaling and Glucose Toxicity in NAFLD

Tobias C. Walther, Harvard School of Public Health, USA

Lipid Droplet Biology in NAFLD

Short Talks Chosen from Abstracts

Tumor Microenvironment and Hepatobiliary Cancers (X6)

Silvia Affo, Columbia University, USA

The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers

Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA

Mechanisms of Immune Escape in Hepatocellular Carcinoma

Alphonse E. Sirica, Virginia Commonwealth University, USA

The Desmoplastic Reaction in Intrahepatic Cholangiocarcinoma: Molecular Drivers and Prognostic Implications

Gregory J. Gores, Mayo Clinic, USA

Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy

Short Talks Chosen from Abstracts

NAFLD and CVD (X5)

Speaker to be Announced

Jay D. Horton, University of Texas Southwestern Medical Center, USA

Molecular Mediators of NAFLD and Hyperlipidemia

Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA

Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets

Short Talks Chosen from Abstracts

Hepatobiliary Cancer Biomarkers (X6)

Yujin Hoshida, UT Southwestern Medical Center, USA

Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts

Irene Oi Lin Ng, University of Hong Kong, Hong Kong

Molecular Biomarkers in Hepatocellular Carcinoma

* Session Chair † Invited but not yet accepted  Program current as of June 20, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers
Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 24

Pathways to NASH (X5)
Speaker to be Announced
Mark A. McNiven, Mayo Clinic, USA
**Lipid Droplet Formation and Lipophagy in Fatty Liver Disease**
Eran Elinav, Weizmann Institute of Science, Israel
**Lipid-Associated Macrophages Control Metabolic Homeostasis**
Speaker to be Announced
Short Talks Chosen from Abstracts

Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)
Xin Wei Wang, NCI, National Institutes of Health, USA
**Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers**
Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
**Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes**
Renumathy Dhanasekaran, Stanford University, USA
**Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma**
Bin Tean Teh, Duke-NUS Medical School, Singapore
**Cholangiocarcinoma in Diverse Populations**
Short Talks Chosen from Abstracts

Emerging Therapies for NASH-I (X5)
Morris J. Birnbaum, Pfizer Inc., USA
**DGAT2 Inhibition for NASH**
Speaker to be Announced
Greg Steinberg, McMaster University, Canada
**Cellular Energy Sensors and Metabolism**
Short Talks Chosen from Abstracts

"Omics" for Precision Medicine of Hepatobiliary Cancers (X6)
Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
**Integrative "Omics" and Precision Medicine for Hepatocellular Carcinoma**
Jesper Beje Andersen, University of Copenhagen, Denmark
**Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications**

THURSDAY, MARCH 25
Departure